Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

The FDA designated Abbott's recall of FreeStyle Libre 3 sensors as the most serious, class I type due to the risk for ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

The US Food and Drug Administration (FDA) has tagged Abbott’s recent recall of its faulty FreeStyle Libre 3 sensors as Class ...

Abbott introduced a revolutionary new device, FreeStyle Navigator, designed to improve the lives of the world’s more than 500 ...

Abbott ABT is facing a challenging business environment globally. Unfavorable foreign exchange impact continues to impede ...

IRVINE, CA / ACCESSWIRE / September 4, 2024 /, Inc., a pioneering leader in the development of advanced diabetes management ...

ABBOTT PARK, Ill. - Abbott has issued a recall for certain FreeStyle Libre 3 sensors due to a risk for inaccurate high glucose readings.

Abbott Diabetes Care, Inc. is recalling its FreeStyle Libre 3 sensors after finding a small number of the sensors may provide incorrect high glucose readings, which, if undetected may pose ...